Pharmaceuticals | Free Full-Text | Therapeutic Potential of Kappa Opioid Agonists
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - ScienceDirect
Difelikefalin: First Approval
Cara Therapeutics: Developing Novel Peripheral Kappa Opioid Product Candidates
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
κ-opioid receptor - Wikipedia
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
1Washington University, St. Louis, MO, USA; 2Trevi Therapeutics, New Haven, CT, USA; 3University of Miami, Miami, FL, USA Introd
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression<b>:</b> A randomized,
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | NEJM
Articles with Cara Therapeutics, Inc. | page 5
A New Path to Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)Friday, March 17, 201712:30 PM – 1:30 PMGrand Caribbean Ballroom 7Loews Sapphire Falls ResortOrlando, Florida Survey
Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis,Neuropharmacology - X-MOL
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
PDF) Purification of a kappa-opioid receptor subtype from frog brain | Mária Szücs, Anna Borsodi, and Kálmán Medzihradszky - Academia.edu
Cara Therapeutics: Scratching At Multiple Indications In 2020 (NASDAQ:CARA) | Seeking Alpha
Cara Therapeutics - Invest In Weed
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Experimental Kappa Opioid Appears Safe and Effective
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Mark
